Related Experiment Video

Updated: Jul 9, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with

Mary L Townsend1, Stephanie B Hollowell, Jasmin Bhalodia

  • 1Department of Pharmacy Practice, Campbell University School of Pharmacy, Buies Creek, NC, USA. townsend@mailcenter.campbell.edu

International Journal of STD & AIDS
|December 13, 2007
PubMed

Insights

Lipid-lowering therapy (LLT) was less effective in HIV-infected individuals compared to the general population. Many HIV patients did not meet cholesterol and triglyceride goals, possibly due to low statin doses.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Hyperlipidemia is a common comorbidity in HIV-infected individuals.
  • Lipid-lowering therapy (LLT) is crucial for managing cardiovascular risk in dyslipidemic patients.
  • Comparative effectiveness of LLT in HIV-infected versus non-HIV-infected populations requires further investigation.

Purpose of the Study:

  • To compare the effectiveness and safety of LLT in HIV-infected individuals with hyperlipidemia against age-matched non-HIV-infected individuals.
  • To assess the achievement of lipid goals in both cohorts receiving LLT.

Main Methods:

  • Retrospective cohort study at Durham Veterans Affairs Medical Center.
  • Inclusion of 53 HIV-infected and 53 age-matched non-HIV-infected subjects receiving LLT.
  • Assessment of LLT efficacy at three and six months, focusing on total cholesterol (TC) and triglyceride (TG) levels.

Main Results:

  • Non-HIV-infected subjects were significantly more likely to achieve TC goals at 3 and 6 months (P = 0.045, P = 0.005) and TG goals at 6 months (P = 0.017).
  • Fewer than 45% of HIV-infected subjects achieved National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) goals at either time point.
  • Overall achievement of NCEP ATP III goals was poor in the HIV-infected cohort.

Conclusions:

  • LLT is less effective in achieving lipid goals in HIV-infected individuals compared to the general population.
  • Suboptimal achievement of lipid goals in HIV patients may be attributed to the use of inappropriately low statin doses.
  • Further research is warranted to optimize LLT strategies for HIV-infected individuals with dyslipidemia.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...